Dashboard
Manage Tickers

KURA Kura Oncology, Inc.

Nasdaq kuraoncology.com


$ 9.73 $ -0.24 (-2.46 %)    

Wednesday, 05-Nov-2025 15:10:30 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 626.25 $ 7.76 (1.25 %)
DIA $ 474.03 $ 3.07 (0.65 %)
SPY $ 680.37 $ 5.34 (0.79 %)
TLT $ 88.97 $ -0.54 (-0.6 %)
GLD $ 367.04 $ 0.59 (0.16 %)
$ 9.96
$ 9.98
$ 9.71 x 856
$ 9.73 x 299
$ 9.69 - $ 10.39
$ 5.41 - $ 19.73
3,398,707
na
866.69M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-04-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-05-2019 12-31-2018 10-K
29 11-05-2018 09-30-2018 10-Q
30 08-06-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 03-12-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-14-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-17-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

kura-oncology-q3-eps-085-misses-084-estimate-sales-20750m-miss-41259m-estimate
Kura Oncology Q3 EPS $(0.85) Misses $(0.84...
11/04/2025 11:34:40

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.8...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

kura-oncology-gets-30m-milestone-payment-under-partnership-agreement-with-kyowa-kirin-in-dosing-first-participant-in-second-komet-017-phase-3-registration-trials-of-ziftomenib
Kura Oncology Gets $30M Milestone Payment ...
11/03/2025 21:11:04

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision ...

kura-oncology-to-feature-results-from-komet-007-combination-trial-of-ziftomenib-oral-investigational-menin-inhibitor-at-ash-2025
Kura Oncology To Feature Results From KOME...
11/03/2025 14:25:08

– Data to be featured in two oral presentations on December 8, 2025 –– Broad development program assesses ziftomenib across div...

kura-oncology-scores-30-million-boost-as-new-leukemia-drug-enters-major-trial
Kura Oncology Scores $30 Million Boost As ...
10/24/2025 16:17:11

Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline.

kura-oncology-receives-30m-development-milestone-payment-under-its-collaboration-with-kyowa-kirin-from-dosing-first-patient-in-komet-017-phase-3-trial
Kura Oncology Receives $30M Development Mi...
10/24/2025 11:03:24

jmp-securities-reiterates-market-outperform-on-kura-oncology-maintains-24-price-target
JMP Securities Reiterates Market Outperfor...
10/20/2025 13:37:22

JMP Securities analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 pr...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
10/20/2025 11:49:25

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $40 price t...

reported-saturday-kura-oncology-presents-new-esmo-2025-data-showing-darlifarnib-plus-cabozantinib-delivers-50-orr-in-rcc-fti-programs-demonstrate-robust-activity-and-manageable-safety-profile
Reported Saturday, Kura Oncology Presents ...
10/20/2025 08:19:09

FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapiesEarly clinical and preclin...

kura-oncology-and-kyowa-kirin-announce-dosing-of-first-patient-in-cohort-of-komet-007-clinical-trial
Kura Oncology And Kyowa Kirin Announce Dos...
10/01/2025 11:11:48

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhib...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
09/30/2025 10:54:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $40 price t...

kura-oncology-and-kyowa-kirin-dose-first-patient-in-phase-3-komet-017-trial-of-ziftomenib-for-frontline-acute-myeloid-leukemia
Kura Oncology And Kyowa Kirin Dose First P...
09/29/2025 20:01:50

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

kura-oncology-announces-the-journal-of-clinical-oncology-published-the-full-results-from-the-pivotal-komet-001-clinical-trial-evaluating-ziftomenib-komet-001-in-rr-npm1-m-aml-met-its-primary-endpoint-with-ziftomenib-monotherapy-demonstrating-significant-clinical-benefit-and-deep-responses
Kura Oncology Announces The Journal Of Cli...
09/25/2025 21:25:17

SAN DIEGO and TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd.

kura-oncology-showcases-preclinical-data-targeting-resistance-pathways-highlights-ko-2806-combo-potential-ahead-of-esmo-2025
Kura Oncology Showcases Preclinical Data T...
09/16/2025 20:02:38

Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 21:06:08

syndax-gains-attention-with-strong-drug-portfolio-path-to-leukemia-market-growth
Syndax Gains Attention With Strong Drug Po...
09/04/2025 19:17:43

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term pro...

this-hubspot-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This HubSpot Analyst Begins Coverage On A ...
09/04/2025 14:14:40

guggenheim-initiates-coverage-on-kura-oncology-with-neutral-rating
Guggenheim Initiates Coverage On Kura Onco...
09/04/2025 14:00:04

Guggenheim analyst Brad Canino initiates coverage on Kura Oncology (NASDAQ:KURA) with a Neutral rating.

evolv-technologies-precigen-hesai-group-and-other-big-stocks-moving-higher-on-friday
Evolv Technologies, Precigen, Hesai Group ...
08/15/2025 14:14:01

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION